HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO BeiGene Ltd - The Future Performance Means a Lot

China Healthcare Weekly (Dec.3)-2021 Insurance Negotiation Results,new COVID Virus,a Rational Return

Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation

Jiangsu Hengrui Medicine (600276.CH) - Insights on Recent Pullback and Future Business Prospects

Jiangsu Hengrui Medicine (600276.CH) - The Concerns and the Outlook

Innovent Biologics Inc (1801.HK) - The PD-1 Outlook and Other Concerns

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Equity Bottom-Up

Jiangsu Hengrui Medicine / Equity Bottom-Up

<ul>
<li>We analyzed the logic and the potential impact of the deal with CStone for CS1002 as well as the accounting estimate change related to R&amp;D spending.</li>
<li>There could be some share price rebound due to the short-term catalyst, and investors could choose to take advantage of it.</li>
<li>However, Hengrui has not been in its best time yet, and the Company still needs time for rebalancing. So, we remain conservative about the outlook at the current stage.</li>
</ul>


We analyzed the logic and the potential impact of the deal with CStone for CS1002 as well as the accounting estimate change related to R&amp;D spending.
There could be some share price rebound due to the short-term catalyst, and investors could choose to take advantage of it.
However, Hengrui has not been in its best time yet, and the Company still needs time for rebalancing. So, we remain conservative about the outlook at the current stage.


Jiangsu Hengrui Medicine (600276.CH)-The Deal with Cstone,the Accounting Estimate Change and Outlook